A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Phase 1
Recruiting
- Conditions
- Myelodysplastic SyndromesAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- GluBio Therapeutics Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06146257
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center-David H. Koch Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath